JANX
Janux Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.96
P/S
50.49
EV/EBITDA
-6.65
DCF Value
$-2.66
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
47.2%
Operating Margin
-881.8%
Net Margin
-635.5%
ROE
-11.5%
ROA
-11.3%
ROIC
-16.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $7.9M | $-31.9M | $-0.51 |
| FY 2025 | $10.0M | $-113.6M | $-1.83 |
| Q3 2025 | $10.0M | $-24.3M | $-0.39 |
| Q2 2025 | $0.00 | $-33.9M | $-0.55 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.81
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.